Abstract
Sorafenib, a multikinase inhibitor that hinders tumor proliferation and promotes apoptosis,1,2 is approved for patients with different solid organ cancers, including thyroid, hepatocellular, and renal cell carcinoma. Treatment with sorafenib can be optimized by identifying and managing specific side effects, such as dose reduction in patients who experience diarrhea. One of the proposed mechanisms of sorafenib-induced diarrhea is pancreatic insufficiency3; pancreatic atrophy has been reported on computed tomography (CT) in patients treated with sorafenib.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call